| The main way pain medicines can affect Lipitor (atorvastatin) effectiveness is by changing how much atorvastatin the body absorbs. |
Cannot Determine |
Supplied label excerpts do not address absorption effects of “pain medicines” on atorvastatin. |
Moderate |
| The main way pain medicines can affect Lipitor (atorvastatin) effectiveness is by changing how fast atorvastatin is broken down in the body. |
Cannot Determine |
Label excerpt shows atorvastatin is metabolized by CYP3A4 (Section 7.1), but does not identify “pain medicines” as affecting metabolism. |
Moderate |
| Some pain relievers can raise the risk of side effects with Lipitor, especially muscle injury. |
Cannot Determine |
Section 5.1 supports statin muscle risk and Section 7 supports increased myopathy risk with certain concomitant drugs; no excerpt specifies pain relievers (acetaminophen/NSAIDs/opioids) as such. |
Moderate |
| An increased risk of side effects can limit how confidently a prescriber keeps a patient on the statin. |
Cannot Determine |
Label supports that therapy may be withheld/discontinued with serious myopathy (Section 5.1), but does not address prescriber confidence or “pain relievers” specifically. |
Informational |
| Acetaminophen does not typically reduce atorvastatin levels in the way strong interaction drugs do. |
Cannot Determine |
No acetaminophen-specific interaction content in provided label excerpts. |
Moderate |
| The bigger concern with acetaminophen is liver stress at high doses or with alcohol. |
Cannot Determine |
Label excerpt includes liver dysfunction warnings for atorvastatin and liver monitoring (Sections 4.1 and 5.2), but does not discuss acetaminophen/alcohol liver stress in relation to LIPITOR. |
Moderate |
| Statins involve liver monitoring. |
Partially Supported |
Supported for atorvastatin: Section 5.2 recommends liver function tests prior to and at 12 weeks following initiation and periodically thereafter. |
Informational |
| NSAIDs generally don’t directly block atorvastatin’s absorption. |
Cannot Determine |
No NSAID-specific absorption interaction content in supplied label excerpts. |
Moderate |
| NSAIDs usually do not reduce Lipitor efficacy in a straightforward way that results from less drug reaching the blood. |
Cannot Determine |
No NSAID efficacy/PK effect statements in supplied label excerpts. |
Moderate |
| Combining NSAIDs with other therapies can complicate tolerability. |
Cannot Determine |
General tolerability with opioids/NSAIDs is not addressed in supplied label excerpts. |
Informational |
| In people with kidney disease or other risk factors, NSAIDs can create conditions that indirectly make side effects harder to manage. |
Cannot Determine |
Supplied label excerpts do not provide NSAID-in-kidney-disease interaction/tolerability statements. |
Moderate |
| Even when a pain medication does not lower atorvastatin levels, it can still affect outcomes by increasing adverse effects. |
Cannot Determine |
Label supports that adverse muscle events can occur and can be increased with certain interacting drugs (Sections 5.1 and 7), but it does not address “pain medications” affecting outcomes via adverse effects. |
Moderate |
| If muscle pain or weakness develops, clinicians may reduce or stop Lipitor regardless of whether atorvastatin absorption was affected. |
Partially Supported |
Section 5.1 supports temporarily withholding or discontinuing LIPITOR in patients with acute, serious conditions suggestive of myopathy; it does not discuss “absorption was affected.” |
Moderate |
| Clinicians may reduce or stop Lipitor based on safety rather than absorption. |
Partially Supported |
Section 5.1 supports withholding/discontinuation for serious myopathy; safety-based dose modification is also reflected in Section 5.2 (dose reduction/withdrawal if ALT/AST elevations persist). |
Informational |
| A patient may perceive Lipitor as less effective when the driver is safety rather than efficacy. |
Cannot Determine |
Supplied label excerpts do not address patient perception in relation to adverse effects. |
Informational |
| Opioids typically do not directly interfere with atorvastatin metabolism like classic drug-interaction triggers. |
Cannot Determine |
No opioid-specific interaction statements in supplied label excerpts. |
Moderate |
| The more relevant issues with opioid use are sedation. |
Cannot Determine |
Label excerpts provided for LIPITOR do not discuss opioids or sedation. |
Informational |
| The more relevant issues with opioid use are constipation. |
Cannot Determine |
Label excerpts provided for LIPITOR do not discuss opioids or constipation. |
Informational |
| Opioid use can affect overall tolerability. |
Cannot Determine |
Label excerpts do not address opioid tolerability in relation to LIPITOR continuation. |
Informational |
| Overall tolerability with opioids can indirectly affect whether Lipitor is continued at full strength. |
Cannot Determine |
Label excerpts do not address this indirect continuation scenario. |
Informational |
| Using the lowest effective pain-med dose for the shortest time can help ensure Lipitor is working while using pain meds. |
Not Addressed |
Label excerpts do not provide guidance about pain-med dosing to preserve atorvastatin efficacy. |
Moderate |
| Patients should watch for statin muscle symptoms, including unusual muscle pain, weakness, and dark urine. |
Partially Supported |
Section 5.1 supports myopathy/rhabdomyolysis and mentions myoglobinuria as part of rhabdomyolysis; provided excerpt does not explicitly list “dark urine” or patient counseling phrasing. |
Moderate |
| Patients should seek care promptly if statin muscle symptoms occur. |
Cannot Determine |
Section 5.1 supports temporarily withholding/discontinuing in serious conditions suggestive of myopathy, but the supplied excerpts do not provide patient “seek care promptly” instructions. |
Moderate |
| Patients should follow up with lipid testing and clinician guidance rather than assuming the statin is failing. |
Not Addressed |
Label excerpt supports lipid levels should be analyzed within 2–4 weeks after initiation/titration (Section 2.1), but does not provide the specific counseling “rather than assuming statin is failing.” |
Informational |
| The response depends on the specific name(s) and dose(s) of the pain medication and whether use is short-term or chronic. |
Cannot Determine |
No label excerpt provided addresses which pain medications interact with atorvastatin, or how short-term vs chronic use changes risk/interaction. |
Informational |